Precipio (NASDAQ:PRPO) Shares Pass Below Two Hundred Day Moving Average – Should You Sell?

Posted by Brenda Bartman on Jun 9th, 2026

Shares of Precipio, Inc. (NASDAQ:PRPO – Get Free Report) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $25.23 and traded as low as $22.75. Precipio shares last traded at $23.00, with a volume of 39,318 shares trading hands.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Wall Street Zen downgraded Precipio from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Precipio in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Get Our Latest Research Report on PRPO

Precipio Price Performance

The company has a current ratio of 1.56, a quick ratio of 1.33 and a debt-to-equity ratio of 0.05. The company has a 50 day moving average price of $26.68 and a 200 day moving average price of $25.23. The company has a market capitalization of $41.17 million, a P/E ratio of -48.94 and a beta of 1.30.

Precipio (NASDAQ:PRPO – Get Free Report) last issued its earnings results on Thursday, May 14th. The biotechnology company reported ($0.81) EPS for the quarter. Precipio had a negative return on equity of 6.73% and a negative net margin of 3.57%.The business had revenue of $6.71 million for the quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Susquehanna International Group LLP bought a new position in shares of Precipio during the 3rd quarter worth approximately $194,000. Renaissance Technologies LLC boosted its stake in shares of Precipio by 10.7% during the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after acquiring an additional 1,400 shares during the period. Geode Capital Management LLC boosted its stake in shares of Precipio by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 789 shares during the period. Evernest Financial Advisors LLC bought a new position in shares of Precipio during the 3rd quarter worth approximately $374,000. Finally, Topline Capital Management LLC bought a new position in shares of Precipio during the 3rd quarter worth approximately $1,158,000. 10.45% of the stock is currently owned by institutional investors.

About Precipio

(Get Free Report)

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.